AustralianSuper Pty Ltd Sells 611,726 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

AustralianSuper Pty Ltd trimmed its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,893,376 shares of the company's stock after selling 611,726 shares during the quarter. AustralianSuper Pty Ltd owned approximately 0.70% of Teva Pharmaceutical Industries worth $142,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in TEVA. Sequoia Financial Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock worth $2,025,000 after purchasing an additional 805 shares in the last quarter. Edmond DE Rothschild Holding S.A. boosted its position in Teva Pharmaceutical Industries by 4.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company's stock worth $346,000 after purchasing an additional 947 shares during the last quarter. Signaturefd LLC boosted its position in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company's stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Teva Pharmaceutical Industries by 9.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company's stock valued at $191,000 after buying an additional 1,180 shares during the last quarter. Finally, QRG Capital Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company's stock valued at $2,355,000 after buying an additional 1,191 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.14 during trading hours on Thursday, hitting $18.45. The stock had a trading volume of 6,881,537 shares, compared to its average volume of 9,295,654. Teva Pharmaceutical Industries Limited has a one year low of $8.42 and a one year high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The stock's 50-day moving average price is $18.03 and its two-hundred day moving average price is $16.88. The stock has a market capitalization of $20.90 billion, a price-to-earnings ratio of -45.00, a PEG ratio of 1.29 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion for the quarter, compared to analysts' expectations of $3.99 billion. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TEVA shares. Argus upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. UBS Group upped their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Finally, Barclays increased their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.